Brief: ICAD's Xoft Brain IORT Shows Improvement In Survival In Recurrent Glioblastoma
31/08/2021 14:33
Aug 31 (Reuters) - ICAD Inc ICAD.O :
* ICAD’S XOFT BRAIN IORT DEMONSTRATES SIGNIFICANT
IMPROVEMENT IN
OVERALL SURVIVAL IN RECURRENT GLIOBLASTOMA ACCORDING TO
COMPARATIVE STUDY
Source text for Eikon: ID:nGNX4sCtRF
Further company coverage: ICAD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on icad
See all newsIcad Inc Reports Results For The Quarter Ended March 31: Earnings Summary
Brief: iCAD, Inc. Q1 Gross Profit USD 4.2 Million
Icad Inc Expected To Post A Loss Of 6 Cents A Share: Earnings Preview
U.S. RESEARCH ROUNDUP- Cognex, Equifax, Netflix
RadNet falls after $103 million all-stock acquisition to buy iCAD